Since 1976, patients grafted at the HBpital Saint-Louis for Fanconi anemia (FA) without evidence of leukemic transformation have been given a uniform conditioning regimen that consisted of low-dose cyclophosphamide (Cy) and thoracoabdominal irradiation (TAI). The use of low-dose Cy raised the question of whether it is sufficient for the establishment of a complete hematopoietic chimerism in all patients. We therefore initiated a study of chimerism early during hematopoietic reconstitution after bone marrow transplantation (BMT) and thereafter in transplanted FA patients. Minisatellite probes were used after DNA amplification by the polymerase chain reaction (PCR). From July 1989 to October 1992, 24 consecutive patients underwent BMT for FA, 19 of whom were assessable for chimerism. Our results using this sensitive technique showed that, among these 19 patients, all but one successfully engrafted. Engraftment was complete early after BMT in 12.
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ANCON1 ANEMIA (FA) is a rare autosomal recessive F disorder characterized by a progressive pancytopenia and diverse congenital abnormalities.'v2 Patients with FA show an increased number of spontaneous chromosome aberrations as compared with the normal p~pulation,~ and, more importantly, a sensitivity of chromosomes to various clastogenic agents that is a characteristic feature of FA.M It has been recognized that clinical presentation FA is so variable that diagnosis based on clinical manifestations alone is difficult and often ~nreliable.~,~ Stahdee et a19 recently demonstrated that FA cell lines can be classified in at least four different complementation groups and they have cloned a gene (FACC) corresponding to one of these complementation group^.'^ Another characteristic of the disease is an increased risk for developing malignancies.",'2 Aplasia in FA patients is usually initially responsive to androgen thera~y . '~, '~ However, in the majority of the patients, pancytopenia returns despite the continued androgen therapy, or the patient develops acute 1e~kemia.I~ As FA is always a fatal disease, bone marrow transplantation (BMT) has now been used to treat almost 100 patients affected with this disease.'^'^ We recently surveyed our results using BMT in 58 FA patients grafted between 1976 to 1992 at the HGpital Saint-Louis. This will be the subject of another report. Our first five patients received high-dose cyclophosphamide (Cy) as conditioning regimen ( 100 to 200 mg/kg).I6 In our experience, using high-dose Cy led to an unexpected toxicity, with only one of these five patients currently surviving 16 years' ~o s~-B M T . '~ We postulated that this abnormal sensitivity to alkylating agents was the in vivo equivalent of the increased in vitro sensitivity of FA cells to DNA cross-linking agents. This has been confirmed by in vitro analysis.18 Furthermore, the increased radiosensitivity of patients with FA" led us to reduce the thoracoabdominal irradiation (TAI) TAI dose from 6 CY, as usually administered in our institution to patients with acquired aplastic anemia,20 to 5 Gy. Therefore, since 1978, FA paThe persistence of a small proportion of recipient's cells was detected in six. This partial hematopoietic chimerism was demonstrated to be only transient in at least five of the six patients. The one patient who failed to engraft showed a recipient-type profile for circulating cells early posttransplantation, indicating autologous bone marrow recovery. A second graft in this patient was also rejected. For both transplantations, the patient was grafted from a matched, unrelated donor. Therefore, 17 of 17 patients successfully grafted and with complete follow up data presented complete hematopoietic chimerism, within the sensitivity limit of the method used. In conclusion, lowering the Cy dose in the conditioning regimen of patients with FA could still allow complete engraftment to occur, at least in patients with an identical sibling donor. tients without evidence of leukemic or preleukemic transformation are given a uniform conditioning regimen consisting of low-dose (20 mg/kg) Cy and 5 C y TAL Reducing the immunosuppressive intensity of the conditioning regimen raised the possibility that it could be insufficient for the establishment of complete hematopoietic chimerism in all patients. Patients with a significant proportion of hematopoietic cells of host origin could thus remain at risk for the development of leukemia in recipient cells. Furthermore, graft rejection may occur in up to 20% of aplastic anemia patients receiving BMT. Factors influencing graft rejection remain unclear, but number of cells infused, sensitization to prior blood transfusion, the use of cyclosporine as graft-versus-host disease (GVHD) prophylaxis, and irradiation within the conditioning regimen appear important.*O For these reasons, we thought it was important to monitor chimerism early during hematopoietic reconstitution after BMT and thereafter. This was performed by a sensitive method using minisatellite probes after DNA amplification by the polymerase chain reaction (PCR). 
MATERIALS AND METHODS

Patients
From July 1989 to October 1992,24 consecutive patients underwent BMT for FA at our institution. In addition, three patients underwent transplantation using cord blood as a source of transplantable cells, as previously described." They are excluded from this analysis. Of the 24 patients who underwent BMT, 19 were assessable for chimerism. The five remaining patients were not assessable due to early death of the following causes: sudden unexplained death in two (day +5 and day +8), interstitial pneumonitis in two, and systemic fungal infection in one. Patients were aware of the objectives of the study and specimens were collected according to the rules established by the local ethical committee of HBpital Saint-Louis. Table I summarizes the clinical characteristics of the recipients. At the time of BMT, the mean age was 10.5 years (range, 4 to 23). Donors and recipients were systematically screened by means of cytogenetics. All patients had typical cytogenetic abnormalities, the frequencies of which increased on incubation with nitrogen mustard of course, none of the selected donors presented such abnormalities. Eleven patients had been given transfusions and one was refractory to random platelet transfusions. Eight patients had been previously treated with androgens and/or corticosteroids. All but four patients received a low dose of Cy (20 mg/kg) plus TAI (5 Gy) as conditioning regimen, and cyclosporine alone for GVHD prophylaxis as previously described.I6 Four patients were given more than 20 mg/kg Cy (Table I ) because of a preleukemic state as assessed by a clonal cytogenetic abnormality [SLA 232, 7q-; SLA 240, t(12; I8)] or because transplantation was performed from a matched, unrelated donor (SLA 258 and 270). Of the 19 patients assessable for chimerism, 14 were grafted from an HLAidentical sibling donor, one from his phenotypically identical father, and four from a matched, unrelated donor. None of the patients had ex vivo T-cell depletion of the donor bone marrow. A mean of 3 X 10' nucleated cells per kilogram was injected. A mean 0.5 X IO9 neutrophils/L and 20 X IO9 platelets/L, independently of transfusion, was reached at the expected time (1 1 to 21 days' posttransplantation) for all patients grafted with an identical sibling donor. Engraftment was delayed for patients grafted with a matched, unrelated donor (2 I to 32 days' posttransplantation). One patient (SLA 227) was grafted twice with marrows from two different matched, unrelated donors. The first transplantion was performed after a low-dose Cy/TAI conditioning regimen and led to graft rejection (see Results). The second transplantation was performed after another conditioning including busulfan, Cy, and antithymocyte globulin (see Results).
Methods
Heparinized blood, 20 to 40 mL, was collected before transplantation from each donor-recipient pair and then at least once after BMT. Genomic DNA was extracted either from whole blood samples or after lymphocytes and polymorphonuclear (PMN) cell separation," the latter technique being used provided that enough nucleated cells could be collected.
PCR amplification and molecularprobes. PCR amplification of minisatellite sequences 33.6 and MS5 I was performed as described by Jeffreys et al. 23 ,24 Samples were handled with gloves in a laminar vertical air-flow hood using positive displacement pipettes exclusively assigned to PCR experiments. After amplification, samples were analyzed by Southern blotting as previously described." The 33.6 probe was prepared as described** and the MS51 probe was labeled by random priming (Amersham Megaprime and DNA labeling system; Amersham, Les Ullis, France). Three donor-recipient pairs (SLA 240, 241, and 244), noninformative at the 33.6 and MS51 loci, were also studied at the YNZ22 locus.2s Amplification of this locus was performed as described by Ugozoli et The YNZ22 probe was prepared by in vitro polymerization with T4 DNA ligase of a synthetic double-stranded oligonucleotide. It was labeled by random priming.
Preparation ofDNA samples.
RESULTS
Analysis of genomic D N A extracted from peripheral blood samples collected from the donor and from the recipi- ent before and after transplantation was performed by PCR amplification. We,22 as well as have estimated the sensitivity of PCR amplification of minisatellite sequences (ie. the ability to detect cells representing a small percentage of the population) to be 1 % to 0.1 %. Engraftment was demonstrated to occur in I8 ofthe 19 patients we studied. For 12 patients, the earliest and all subsequent samples analyzed showed a donor-type profile for circulating nucleated cells (early complete engraftment), with no detection of recipient cells within the sensitivity limit of the method used (Fig I) .
A small proportion of recipient cells was found in six patients (SLA 220,228, 241, 244,245, and 264), indicative of a partial hematopoietic chimerism ( Table 2) . These residual recipient cells were detected only transiently in five patients (SLA 220, 228, 241, 245. and 264). and were not detectable by PCR amplification of minisatellite sequences later on. These patients with transient persistence of recipient cells differ in the fraction in which these residual cells were detected. For patient SLA 220, they were detected in whole blood on day 33, but were no longer present on day 100 in either lymphocyte or PMN cell fractions. Similarly, in patient SLA 228, recipient cells were detected on day 4 I (whole blood sample), but not later. Patient SLA 245'had residual recipient cells in a whole blood sample on day 3 I, and in both the lymphocyte and PMN cell fractions on day 77. Only donor cells could be detected in both fractions on day 488 (Fig 2) . A similar pattern of partial hematopoietic chimerism occurred in patient SLA 241, who had persistence of recipient cells in both fractions on day 28 and 100 and detection of only donor cells in both fractions on day 5 I 1. Patient SLA 264 showed a different pattern. He had persistent recipient cells only in the lymphocyte fraction on day 48, while analysis of the PMN fraction on the same blood sample showed only a donor-type profile. On day 98, analysis showed a donor-type profile for both fractions (Fig  3) . Patient SLA 244 could only be studied on day 95 post-BMT. Residual recipient cells were detected in both the lymphocyte and PMN cell fractions. Since in six patients host cells were found at least transiently after transplantation, and since partial hematopoietic chimerism may be associated with a lessened incidence of GVHD,27 we compared the incidence of GVHD in these six patients and in those who showed early complete donor-derived hematopoiesis posttransplant ( a persistence of recipient cells after engraftment (Fig 4) . This led to bone marrow failure and late graft rejection.
DISCUSSION
In this study of a cohort of 19 consecutive patients grafted for FA who received low-dose Cy as part of their condition- ing regimen, our aim was to determine whether complete engraftment occurs after BMT, as we previously found for acquired aplastic anemia patients, or whether partial hematopoietic chimerism, transient or stable, can be detected. To perform this study, we used the same methodology as in our previous study,22 ie, PCR amplification of the minisatellite sequences, which improves the detection of small amounts of residual host ~e I l s .~~*~"~O Using this approach for studying chimerism status of patients grafted for acquired aplastic anemia, we previously found that three of I5 donor-recipient pairs had noninformative profiles, since donor and recipient shared the same alleles at the 33.6. locus. This problem has been solved in the present study with the use of additional probes. Among the 19 donor-recipient pairs analyzed in the present study, all but three were shown to have an informative profile for at least one of the two systematically analyzed minisatellite loci (33.6. and MS5 I). The analysis of three other donor-recipient pairs was not informative due to common alleles at both the 33.6. and MS5 1 loci. The use of a third probe (YNZ22) ailowed us to analyze the entire patient population.
Among the 19 patients studied, all but one successfully engrafted. Engraftment was complete early after BMT in 12 patients. The persistence of a small proportion of recipient's cells was detected in six patients. The incidence of partial hematopoietic chimerism in this study was therefore 33%. More importantly, the persistence of host cells was demonstrated to be only transient in at least five of six patients.
Thus, at least I7 of 19 patients have, in fine, a complete donor-type profile of circulating cells, indicating complete engraftment within the sensitivity limit of the method used. We have previously reported that two of three long-term survivor FA patients who underwent BMT after a low-dose Cy and TAI conditioning regimen presented a mixed blood cell population after BMT.3' It was therefore argued that this modified conditioning regimen could be insufficient for Abbreviations as in Fig 1. the establishment of complete hematopoietic chimerism in all patient^.^' In the present study, we do not confirm our preliminary results of partial hematopoietic chimerism occumng in FA patients after BMT. This may be due to the fact that these preliminary results were obtained by Southem blot analysis with a multilocus minisatellite probe and that the DNA ofthe recipient before BMT was not ava'ilable for analysis. To the best of our knowledge, four different groups have published results on BMT in FA patient^.^'"^ In these studies, engraftment was assessed by means ofcytogenetics in sex-mismatched cases or by red blood cell phenotyping. Details on the chimerism status of the patients were not reported, with only "take" or "rejection" as described parameters. Thus, a direct comparison with our study is not possible, especially with regard to an eventual difference in the chimerism status that could have been related to the use of conditioning regimens that were different)' or similalJ4 to that used in our study. Lawler et aIz8 reported the case of a patient grafted for FA after a low-dose Cy/TAI conditioning regimen who exhibited transient partial hematopoietic chimerism.
Residual host cells were detected in six patients and could be demonstrated to be transient in five patients, with the sixth one not available for serial chimerism analysis. The occurrence of circulating cells of mixed origin in six of 19 patients after BMT for FA was compared with our results of a short-term study of chimerism in patients grafted for acquired aplastic anemia." In this previous study, all 10 patients grafted from an HLA-identical sibling donor after a high-dose CyITAI conditioning regimen exhibited a donortype profile on all analyzed samples using the same methodology as in the present study. However, this difference (six of 18 FA patients with partial chimerism, as compared with zero of IO patients with acquired aplastic anemia) does not reach statistical significance (P = .062 two-sided Fisher's exact test). Partial chimerism was shown by others to occur after BMT for acquired aplastic anemia in patients who were delivered a high dose of Cy alone as conditioning regimen. In the largest study published by the Seattle group, 56 of96 patients(58%) had a mixed blood cell population early after transplantation (mean, 18 days' post-BMT), as assessed by cytogenetic analysis. Of these 56 patients, 35 evolved toward complete hematopoietic chimerism (median, 54 days ~o s~-B M T ) .~~ More recently, results obtained by PCR amplification after BMT for acquired aplastic anemia or thalassemia have also shown that a significant proportion of these patients grafted for nonmalignant hematologic diseases are transient partial hematopoietic chimera^.^^^^*^* Several recent studies on partial chimerism after BMT using PCR amplification to monitor engraftment dealt with patients grafted for malignant diseases, and a significant proportion of them were grafted with T-celldepleted marrow^.^^^*^^ In these studies, the incidence of partial chimerism has been clearly linked to T-cell depletion of the graft, confirming older studies that used cytogenetics or restriction fragment length polymorphism.4042 In our study, none of the patients received T-cell-depleted marrow.
Conversely, it is possible that if a larger number of patients would have been included in our study, the trend for a higher incidence of partial chimerism after BMT in FA patients could have reached significance. In that case, a possible explanation of the incidence of transient partial hematopoietic chimerism in our FA patients could be the use of our modified conditioning regimen. In addition, it has been shown that cultured FA cells exhibit a specific endogenous cell-cycle defect, with a G2 phase of about twice the normal Thus, detection of residual recipient cells in patients grafted for FA might, at least in part, be due to the detection of these long-life cells. We are currently extending our study to include a larger number of patients.
Since partial chimerism might be restricted to some specific lineage, we have monitored chimerism in two separated fractions, ie, lymphocyte-and PMN cell-enriched fractions obtained by Ficoll gradient centrifugation. This allowed us to find two types of partial hematopoietic chimerism. The first type is characterized by the presence of residual recipient cells in the lymphocyte fraction only. This could represent what has been described by others as longlived radioresistant host lymphocyte^.^^,^.^^ In the second type, residual recipient cells were detected in both the PMN cell and lymphocyte fractions, suggesting transient coexistence of donor and recipient hematopoiesis or, more likely, differentiation of immature host progenitors. These complex forms of partial chimerism could be more precisely assessed by combining fluorescent-activated cell sorting of the different blood cell populations and PCR amplification analysis."
The lessened incidence ofGVHD in patients with aplastic anemia with partial hematopoietic chimerism was first pointed out by the Seattle group37 and has been recently reviewed by McCann and L a~l e r .~~
In the present study, no statistical correlation was found between partial hematopoietic chimerism and acute or chronic GVHD. However, this lack of statistical significance may be due to the number of patients studied and larger numbers would perhaps show a significant difference. This question might be resolved in the future by our, still ongoing, chimerism study on grafted patients with acquired or constitutional aplastic anemia.
One patient in this study showed a recipient-type profile for circulating cells early post-BMT (days 2 1 and 28), indicating autologous bone marrow recovery. Subsequently, this patient underwent a second transplantation and study of his chimerism status showed evidence for a successful early engraftment followed by a late marrow failure due to rejection. It must be emphasized that for both transplantations this patient has been grafted from a matched, unrelated donor. We have previously shown that, for patients with acquired aplastic anemia, there was a statistically significant difference in outcome between patients grafted with an identical sibling donor and those grafted from a different type of donor.22 The late rejection observed during the follow-up of this patient might therefore be attributed to an immune-mediated host reaction against the graft of a matched, unrelated donor. Such "no take" or rejection has also been described by Hows et a134 in four of nine patients with FA who received T-cell-depleted marrows from alternative donors after a low-dose Cy conditioning regimen. In the present study, five patients were grafted from an altemative donor (matched, unrelated, four patients: phenotypically identical father, one patient) and only one underwent autologous bone marrow recovery, as compared with none of the 15 patients grafted with an identical sibling donor.
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The difference is nonsignificant by the two-sided Fisher's exact test.
In conclusion, in this study involving 19 patients grafted for FA after a low-dose Cy/TAI conditioning regimen, one patient grafted with a matched, unrelated donor rejected his graft twice, and partial hematopoietic chimerism was detected in six patients. However, this status was transient in the five patients with available follow-up data. Therefore, 17 of 17 patients successfully grafted and whose follow-up was possible presented infine a complete hematopoietic chimerism. Thus, lowering the Cy dose in the conditioning regimen of patients with FA could still allow complete engraftment to occur, at least in patients grafted with an identical sibling donor.
